2022 full-year results:
Revenue up 41%.
Positive EBITDA for the year.
A sharp improvement in results, in line with guidance.
Well positioned to confirm this trajectory in 2023.
Strengthened cash flow.
More information at: CP-VOGO-RA-2022-EN.pdf (vogo-group.com)
Share this article:
COVID-19 – VOGO participation in the development, production and distribution of a rapid saliva-based screening test VOGO is honored to announce today, that it is collaborating with scientists from the CNRS (French National Center for Scientific Research) laboratory Sys2Diag, and with biotechnology company SkillCell for providing a rapid saliva-based screening test, if the results of…